Efficacy and Safety of Biological DMARDs: A Systematic Literature Review Informing the 2022 Update of the ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis
Ann Rheum Dis 2022; online ahead of print doi:10.1136/ard-2022-223298
New evidence supports the efficacy and safety of TNFi (originators/biosimilars) and IL-17i in r-axSpA and nr-axSpA. This systematic literature review was conducted to inform the taskforce of the 2022 update of the ASAS-EULAR recommendations.
Interestingly, IL-23i failed to show relevant effects. Observational studies are needed to confirm long-term IL-17i safety. This review informed the 2022 ASAS-EULAR management recommendations for axSpA, highlighting new evidence on efficacy and safety of existing and new bDMARDs
Keywords:
